OK BIOTECH Business Summary

OK BIOTECH (4155.TW), known locally as 訊映, is a prominent Taiwan-based medical device manufacturer specializing in the research, development, and global distribution of blood glucose monitoring systems (BGMS). The company generates the vast majority of its revenue—approximately 80%—from the high-margin sale of disposable blood glucose test strips, with the remaining 20% derived from glucose meters, portable nebulizers, and OTC hearing aids under its "OK Good Sound" line. OK BIOTECH employs a dual-track commercial strategy, marketing products under its proprietary OKB and Prodigy (U.S. subsidiary) brands while providing extensive OEM/ODM services for international healthcare partners. Within the competitive landscape, the company contends directly with Taiwanese peers such as TaiDoc Technology (4736.TW), ApexBio (4104.TW), and Bionime (4737.TW), positioning itself as a vertically integrated, cost-efficient specialist in the home healthcare and chronic disease management sectors across 60 countries. The company was founded in 2004 by current Chairman and General Manager (CEO) Chia-Te Lai, an industry veteran with a Master’s in Industrial Engineering and Management from National Chiao Tung University. The executive leadership team includes Vice Chairman Liu You-Ci, who previously served as a key strategic assistant to the General Manager, and CFO Hou Chi-Cheng, who oversees financial operations and serves as the primary corporate spokesperson. The board is supported by a mix of institutional and private investment entities, including Shang Shun Investment and Ting Fa Investment, reflecting a stable ownership structure rooted in Hsinchu’s high-tech medical cluster. Under this leadership, OK BIOTECH has successfully transitioned from a regional manufacturer to a globally recognized provider with FDA, CE, and MDSAP certifications, maintaining a strong operational focus on automated production and R&D innovation.